

# CTT Pharmaceuticals Provides Corporate Update for Shareholders

21.04.2015 | [The Newswire](#)

[Mindesta Inc.](#) (OTCBB: MDST). CTT Pharmaceuticals Inc. ("CTT Pharma" or the "Company") has issued an update from its president to shareholders. The update is as follows:

To CTT Shareholders:

Let me first take this opportunity to thank you for your continued interest in CTT Pharmaceuticals.

Our gains have been a direct result of the continued support of shareholders like you. At this time, I would like to provide you with an update on our activities and a view towards what is on the horizon for CTT Pharma.

From Q4 of 2014 through to Q1 of 2015, we have been developing, refining and testing formulations of our wafer technology for delivering Cannabinoids through the oral mucosa. The inability for Cannabinoids to be readily absorbed within the mouth - as opposed to through the digestive system - has been a significant challenge for anyone attempting to truly capitalize on the benefits of Cannabinoids.

To date, there have been three key challenges to achieving this:

1. It is more difficult for some Cannabinoids to enter the buccal cavity based on their molecular size and weight.
2. Conversely, THC enters the oral mucosa very easily and requires a combination of Cannabinoids in order to mitigate its hypnotic effect.
3. An effective dosage control method to ensure accurate combinations of Cannabinoids and THC has been elusive to date.

Our R&D has been focused on addressing these challenges and we believe that we have reached a critical milestone. The refinement and testing of our formulation for creating buccal strips has yielded a breakthrough that I am proud to say will enable CTT to set the bar for the Medical Cannabis industry.

Our proprietary formulation enables our wafers to deliver Cannabinoids that effectively enter the blood stream through the buccal cavity. It also allows us to effectively combine Cannabinoids to address various indications because we are now able to quantify dosage levels on a commercially viable scale.

Of note - an outcome of achieving this critical milestone - is a close working relationship with a specialized Cannabis research group in Europe that exponentially extends our research capabilities and global footprint. We are excited by the continued potential that this ongoing collaboration represents for our future growth.

Overall, we believe that we are the only company with a proprietary technology platform that incorporates scientific research best practices. We also believe that we have a distinct advantage by having a medical expert in Dr. Pankaj Modi on board as our CEO. With these unique points of differentiation, we are in an ideal position to disrupt the industry.

With our industry leading formulation in hand, we are in the process of developing a variety of wafers for various indications and initializing animal trials to study and analyze the bioavailability across our CannaWafe(R) and MedWafe(R) product skews. With efficiency being our top priority, we will also conduct analysis and bioavailability trials across our VetWafe(R) skews as a component of the overall animal trial plan. Our short-term goal - at the successful conclusion of these trials - is to patent our new techniques for cannabis extracts and secure further evidence-based research to support our delivery system rollout on a whole.

[Click Image To View Full Size](#)

In addition, we are investigating the costs of creating a GMP facility that would fabricate our CannaWafe(R)

(THC and low-level THC varieties) and MedWafe(R) (Opiate + Cannabinoid/THC combinations) in the future.

In concert with this effort, our executive team is proactively identifying and developing new business opportunities in the form of companies and/or governments who represent promising clients for future growth.

Lastly, we will be raising additional capital and finalizing our rollback as previously announced. Given all of these activities, I hope that you share in my enthusiasm for the future of CTT Pharmaceuticals and I look forward to updating you as we release more exciting news.

Best regards,

Dean Hanisch  
President

**For additional information, please contact:**

Dean Hanisch, President  
CTT Pharmaceuticals  
Tel: 613 612-6060  
website: [www.cttpharmaceuticals.com](http://www.cttpharmaceuticals.com)

**Forward Looking Statements:**

*This press release contains forward-looking statements, which can be identified by the use of statements that include words such as "could", "potential", "believe", "expect", "anticipate", "intend", "plan", "likely", "will" or other similar words or phrases. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. The Company does not intend, and does not assume any obligation, to update forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.*

---

Dieser Artikel stammt von [Rohstoff-Welt.de](http://Rohstoff-Welt.de)

Die URL für diesen Artikel lautet:

<https://www.rohstoff-welt.de/news/197856--CTT-Pharmaceuticals-Provides-Corporate-Update-for-Shareholders.html>

Für den Inhalt des Beitrages ist allein der Autor verantwortlich bzw. die aufgeführte Quelle. Bild- oder Filmrechte liegen beim Autor/Quelle bzw. bei der vom ihm benannten Quelle. Bei Übersetzungen können Fehler nicht ausgeschlossen werden. Der vertretene Standpunkt eines Autors spiegelt generell nicht die Meinung des Webseiten-Betreibers wieder. Mittels der Veröffentlichung will dieser lediglich ein pluralistisches Meinungsbild darstellen. Direkte oder indirekte Aussagen in einem Beitrag stellen keinerlei Aufforderung zum Kauf-/Verkauf von Wertpapieren dar. Wir wehren uns gegen jede Form von Hass, Diskriminierung und Verletzung der Menschenwürde. Beachten Sie bitte auch unsere [AGB/Disclaimer](#)!

---

Die Reproduktion, Modifikation oder Verwendung der Inhalte ganz oder teilweise ohne schriftliche Genehmigung ist untersagt!  
Alle Angaben ohne Gewähr! Copyright © by Rohstoff-Welt.de -1999-2026. Es gelten unsere [AGB](#) und [Datenschutzrichtlinien](#).